What SPRAVATO® Is and How It Differs from Other Treatments
SPRAVATO® is the brand name for esketamine, a medication chemically related to ketamine but administered as a nasal spray rather than an intravenous infusion. The FDA approved SPRAVATO® in 2019 specifically for treatment-resistant depression, making it the first fundamentally new mechanism antidepressant approved in decades. This approval followed rigorous clinical trials demonstrating effectiveness when traditional antidepressants failed.
Esketamine is one of two mirror-image molecules that make up ketamine. Think of it like your left and right hands—they’re similar but not identical. Scientists isolated the esketamine form because research suggested it might provide antidepressant effects with potentially fewer side effects than racemic ketamine (the mixture of both forms used in IV ketamine therapy). This molecular specificity allowed pharmaceutical development and FDA approval process that IV ketamine hasn’t undergone for depression treatment.
The nasal spray delivery method makes SPRAVATO® more convenient than IV infusions in some ways. No needle insertion, no need for IV access, and self-administration under supervision rather than passive receiving of infusion. However, the nasal route requires multiple spray applications and some medication drips down your throat, which some people find unpleasant. Neither delivery method is objectively better—they’re different approaches with individual pros and cons.
SPRAVATO® differs fundamentally from traditional antidepressants in its mechanism. SSRIs like sertraline and SNRIs like venlafaxine work by increasing serotonin or norepinephrine in your brain. These effects take weeks to develop as brain chemistry gradually adjusts. SPRAVATO® targets NMDA receptors and glutamate pathways, producing rapid changes in neural connections. According to clinical trials, statistically significant improvement in depression scores appears within 28 days, with 70% response rate compared to 52% with placebo when combined with oral antidepressants (Popova et al., 2019).
Who Qualifies for SPRAVATO® Treatment
FDA approval for SPRAVATO® includes specific criteria determining medical appropriateness. You must be an adult with major depressive disorder who has tried at least two different antidepressants at adequate doses for sufficient duration without achieving satisfactory improvement. This defines treatment-resistant depression—the condition SPRAVATO® specifically targets.
Insurance companies typically require documentation of previous antidepressant trials before approving SPRAVATO® coverage. This means your medical records should clearly show which medications you tried, at what doses, for how long, and why each was inadequate. Keeping thorough records of your treatment history helps streamline the insurance authorization process when pursuing SPRAVATO® or other treatment-resistant depression interventions.
SPRAVATO® is also approved for major depressive disorder with acute suicidal ideation or behavior. In this indication, SPRAVATO® provides rapid-acting relief during psychiatric crises when patients can’t wait weeks for traditional antidepressants to work. This approval recognizes the urgent need for fast-acting antidepressant interventions in life-threatening situations.
Certain medical conditions preclude SPRAVATO® use. Uncontrolled high blood pressure, aneurysmal vascular disease, bleeding in the brain, or known allergic reactions to esketamine or ketamine make SPRAVATO® inappropriate. Your medical screening before starting treatment identifies these contraindications. The board-certified emergency medicine physicians at Allevate Health have 18+ years of experience evaluating patients for innovative treatments and identifying when SPRAVATO® is medically appropriate versus when alternative approaches make more sense.
The SPRAVATO® Treatment Process
SPRAVATO® isn’t something you pick up at the pharmacy and use at home. It’s administered exclusively in certified healthcare settings under medical supervision because of dissociative side effects and need for blood pressure monitoring. To understand exactly what the experience looks like from arrival to discharge, our What to Expect page gives a step-by-step overview of the Allevate Health patient experience.
Treatment begins with comprehensive evaluation confirming you meet diagnostic criteria for treatment-resistant depression and don’t have medical contraindications. Your provider reviews your medication history, performs physical examination including blood pressure measurement, and discusses what SPRAVATO® treatment involves. This consultation determines whether SPRAVATO® is appropriate and whether your insurance will likely cover treatment.
On treatment days, you arrive at the clinic having avoided food for at least two hours and liquids for 30 minutes beforehand. This reduces nausea risk during treatment. Your blood pressure is measured before receiving medication, as pre-existing elevation might require delay until blood pressure is controlled. Once cleared medically, you self-administer the nasal spray under direct observation of healthcare staff.
The nasal spray comes with specific administration instructions. You spray once in each nostril, wait five minutes, then repeat with a second device. Some people need three devices depending on their prescribed dose. During and after administration, you rest in a comfortable treatment chair while staff monitors you. Dissociative effects typically begin within minutes and peak around 20-40 minutes after administration.
Observation continues for at least two hours after your last spray. During this time, staff monitors blood pressure every 40 minutes and assesses for side effects like dissociation, sedation, or anxiety. You can’t leave until dissociative effects have resolved, vital signs are stable, and you’re alert enough to function safely. Someone must drive you home—driving the rest of the day after SPRAVATO® treatment is prohibited because residual effects impair reaction time and judgment even after you feel subjectively normal.
Treatment Schedule and Duration
SPRAVATO® treatment follows a structured schedule proven effective in clinical trials. The induction phase involves twice-weekly treatments for the first four weeks. This intensive initial schedule establishes therapeutic effects and allows dose optimization based on your response and tolerability.
After completing induction, you transition to maintenance dosing. Weeks 5-8 typically involve weekly treatments. Beyond eight weeks, frequency reduces further to every other week or monthly depending on how well you maintain improvement. This schedule isn’t rigid—your provider adjusts timing based on whether your depression symptoms remain controlled or begin returning between treatments.
The maintenance phase can continue indefinitely for sustained benefit, according to relapse prevention research showing SPRAVATO® combined with oral antidepressants reduces relapse risk compared to oral antidepressants alone (Daly et al., 2019). Many people need ongoing treatment to prevent depression relapse rather than completing a set number of sessions and stopping. Results vary by individual—some people maintain improvement with infrequent treatments while others require more regular sessions to prevent symptom return.
Missing treatments affects outcomes, particularly during the induction phase when therapeutic effects are building. If you must skip a scheduled treatment, contact your provider to discuss rescheduling rather than just extending the gap. Inconsistent treatment during induction may reduce overall effectiveness and delay improvement.
Side Effects and What to Expect
SPRAVATO® causes side effects in most patients, though severity varies considerably. Understanding common side effects helps you prepare rather than being surprised or alarmed when they occur.
Dissociation represents the most prominent side effect—altered perceptions where things feel unreal, your sense of body boundaries changes, or time feels distorted. Most people find dissociation tolerable or even interesting, but some experience anxiety or discomfort during these effects. Dissociation typically resolves within 90 minutes, though mild effects sometimes persist several hours. The monitored setting ensures support if dissociation becomes distressing.
Blood pressure increases temporarily during and after SPRAVATO® administration. For most people, this elevation is modest and returns to baseline within hours. However, significant increases require more intensive monitoring and might necessitate blood pressure medication before future treatments. Pre-existing hypertension must be controlled before starting SPRAVATO®, and ongoing blood pressure monitoring continues throughout your treatment course.
Sedation and dizziness affect many patients during the observation period. You might feel sleepy, lightheaded when standing, or generally uncoordinated. These effects resolve before discharge but explain why you can’t drive afterward. Some people experience mild sedation for several hours after leaving the clinic, so planning rest time after treatment makes sense.
Nausea occurs in some patients, which explains the pre-treatment fasting requirements. Anti-nausea medication can be provided if nausea becomes problematic. The sensation of medication dripping down your throat after nasal administration sometimes triggers nausea even without systemic effects. Taste disturbances—a metallic or unpleasant taste—are common but temporary.
Anxiety or agitation can occur during dissociative experiences, particularly in people with pre-existing anxiety disorders. The medical team can provide reassurance and environmental adjustments (dimmer lighting, reduced noise) to ease anxiety. In rare cases, anti-anxiety medication might be needed. This is why treatment happens in supervised settings rather than at home where you’d manage these experiences alone.
Insurance Coverage and Cost Considerations
SPRAVATO® holds a significant advantage over IV ketamine therapy: insurance coverage. Because SPRAVATO® is FDA-approved specifically for treatment-resistant depression, most major insurance plans cover it when you meet eligibility criteria. This coverage makes SPRAVATO® financially accessible for many people who couldn’t afford private-pay IV ketamine.
Allevate Health is in-network with multiple insurance carriers including Aetna, Blue Cross Blue Shield, Medicare, and Amerigroup/Wellpoint for SPRAVATO® treatment. Being in-network means negotiated rates and direct billing to your insurance rather than requiring full upfront payment with later reimbursement. Your specific out-of-pocket costs depend on your insurance plan’s copays, deductibles, and coinsurance structure. For a complete breakdown of costs and financing options, visit our pricing page.
Prior authorization requirements mean your insurance company reviews medical necessity before approving coverage. Your provider submits documentation showing you meet criteria for treatment-resistant depression—records of previous antidepressant trials that failed to provide adequate benefit. Authorization typically takes several days to weeks depending on insurance company processing times. Starting SPRAVATO® requires completing this authorization process first, which means some delay between deciding to try SPRAVATO® and actually beginning treatment.
For people whose insurance doesn’t cover SPRAVATO® or who don’t have insurance, the medication cost is substantial—typically thousands of dollars per month during induction phase when treatment is twice weekly. The nasal spray devices themselves cost several hundred dollars each, and you need two or three devices per treatment session. Additional costs include the clinic’s administration fees for providing the supervised setting and medical monitoring. These costs make private-pay SPRAVATO® less accessible than insured treatment, which is why insurance coverage represents a major advantage of SPRAVATO® over IV ketamine for many patients.
Comparing SPRAVATO® to IV Ketamine Therapy
Both SPRAVATO® and IV ketamine affect glutamate pathways and show effectiveness for treatment-resistant depression, but they’re not identical treatments. Understanding differences helps you decide which approach better fits your situation.
FDA approval status differs significantly. SPRAVATO® is FDA-approved specifically for treatment-resistant depression, while IV ketamine is used off-label for depression based on research evidence and clinical experience. FDA approval matters for insurance coverage and gives some people confidence that regulatory review confirmed safety and efficacy. Others are comfortable with well-researched off-label uses and don’t prioritize FDA approval.
Administration method and convenience vary between treatments. SPRAVATO® nasal spray takes a few minutes to self-administer under supervision, while IV ketamine requires IV placement and 40-minute infusion. Some people prefer avoiding needles and appreciate the brief SPRAVATO® administration. Others find IV infusions more predictable in dosing and prefer continuous infusion to repeated nasal sprays that drip unpleasantly.
Research base differs in quantity and duration. IV ketamine has been used for decades in anesthesia and more recently for depression, generating extensive research and clinical experience. SPRAVATO® research is newer, focusing on the specific esketamine formulation since its development. Both have solid evidence supporting effectiveness, but IV ketamine’s longer history provides more data on long-term outcomes and different dosing strategies.
Cost and coverage represent the most significant practical difference. Insurance typically covers SPRAVATO® for eligible patients, making out-of-pocket costs relatively low. IV ketamine therapy requires private pay—$600 per session at Allevate Health—which totals approximately $3,600 for a typical initial six-session series. For people with insurance coverage, SPRAVATO® is more affordable. For those paying out of pocket anyway, IV ketamine’s research history and administration method might be preferable despite similar total costs.
Neither approach is universally better—they’re different options with individual advantages. The board-certified physicians at Allevate Health can discuss both SPRAVATO® and IV ketamine during your consultation, helping you understand which treatment better matches your medical history, insurance coverage, preferences, and specific depression pattern.
What Success Looks Like with SPRAVATO®
Treatment response varies significantly between individuals. Some people experience dramatic improvement within the first few treatments. Others notice gradual changes over weeks. Still others have minimal response despite adequate treatment trials. Results vary by individual, and predicting who will respond robustly versus minimally isn’t currently possible before trying treatment.
Improvement often starts with specific symptoms rather than overall mood lifting simultaneously. You might sleep better before feeling happier. Energy might return before interest in activities does. Suicidal thoughts might diminish even while general sadness persists. Tracking individual symptom changes helps recognize progress even when you don’t feel completely better yet.
Partial response is common and valuable even if not achieving complete remission. Reducing depression from severe to moderate meaningfully improves functioning and quality of life. Moving from unable to work to managing part-time employment represents significant progress even if you’re not feeling perfectly normal. Complete symptom elimination isn’t necessary for treatment to be worthwhile.
Maintenance treatment requirements indicate successful response rather than treatment failure. Needing ongoing treatments to maintain improvement doesn’t mean SPRAVATO® didn’t work—it means your depression requires continued intervention to stay controlled, similar to how diabetes or hypertension require ongoing medication. The goal is managing your depression effectively, not necessarily achieving permanent cure allowing discontinuation.
Making Informed Decisions About SPRAVATO®
SPRAVATO® represents a genuine advance for treatment-resistant depression—a new mechanism with FDA approval and insurance coverage making it accessible for many people who previously had limited options. However, it’s not a magic solution that works for everyone or lacks drawbacks.
Consider SPRAVATO® if you meet criteria for treatment-resistant depression, have insurance coverage, and can commit to the required treatment schedule including twice-weekly visits for a month. SPRAVATO® makes particular sense if you’ve exhausted other medication options and need something fundamentally different mechanistically. The insurance coverage advantage over IV ketamine significantly matters if cost is a barrier.
Alternative considerations include IV ketamine if you prefer infusion administration or want access to the longer research history and flexibility in dosing protocols. Traditional medication optimization with augmentation strategies might be appropriate if you haven’t truly maximized standard approaches yet. Some people benefit more from pursuing intensive therapy or addressing contributing factors like sleep disorders before trying ketamine-related treatments.
Talk with your provider about your complete treatment history, what you’ve tried before, what worked partially, what failed completely, and what side effects you’ve struggled with. This comprehensive discussion helps determine whether SPRAVATO® fits your situation or whether other approaches should be prioritized. The physicians at Allevate Health specialize in treatment-resistant depression and can help you evaluate whether SPRAVATO® or alternative treatments better match your needs.
If you’re interested in learning whether SPRAVATO® treatment might be appropriate for your treatment-resistant depression, Allevate Health offers complimentary consultations to review your treatment history and discuss both SPRAVATO® and IV ketamine options. The board-certified emergency medicine physicians can verify your insurance coverage for SPRAVATO®, explain the treatment process, and help you make informed decisions about next steps. Call (640) 252-9785 to schedule your consultation and explore whether FDA-approved SPRAVATO® treatment could provide the relief you haven’t found with traditional antidepressants.
FAQ Section
Q: Can I use SPRAVATO® at home once I’m familiar with the process?
A: No. SPRAVATO® must be administered in a certified healthcare setting under direct observation every single time due to dissociation risks and required blood pressure monitoring. This is a permanent FDA requirement, not just initial training—you’ll never be able to take SPRAVATO® home. If home administration is important to you, SPRAVATO® isn’t the right choice.
Q: How long does it take to know if SPRAVATO® is working?
A: Clinical trials showed statistically significant improvement within 28 days (four weeks of twice-weekly treatment). Some people notice changes sooner—within the first week or two. Others require completing the full induction phase before recognizing improvement. If you’ve completed eight weeks of treatment without any improvement, SPRAVATO® likely isn’t effective for your particular depression pattern.
Q: What happens if I stop SPRAVATO® treatment after it’s working?
A: Depression symptoms often return within weeks to months after stopping SPRAVATO®, which is why most people transition to maintenance dosing rather than stopping completely. Think of SPRAVATO® like other chronic disease treatments—it controls symptoms while you’re using it, but doesn’t permanently cure the underlying condition. Discuss tapering strategies with your provider rather than stopping abruptly.
Q: Can I combine SPRAVATO® with my current antidepressant?
A: Yes, SPRAVATO® is always used in combination with an oral antidepressant—it’s not approved as monotherapy. You continue your current antidepressant while adding SPRAVATO® to the regimen. In fact, insurance companies typically require ongoing oral antidepressant use as a condition of covering SPRAVATO® treatment.
References
Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., Thase, M. E., Zajecka, J., Winokur, A., Divacka, I., Fagiolini, A., Cubala, W. J., Bitter, I., Blier, P., Shelton, R. C., … Singh, J. B. (2019). Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression. JAMA Psychiatry, 76(9), 893-903. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2730826
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., Molero, P., Vieta, E., Bajbouj, M., Manji, H., Drevets, W. C., & Singh, J. B. (2019). Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression. JAMA Psychiatry, 76(4), 428-438. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2725074
U.S. Food and Drug Administration. (2019). FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified